Patents by Inventor Matthew Cullen

Matthew Cullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteasome activity enhancing compounds
    Patent number: 11958873
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: April 16, 2024
    Assignee: Kineta, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20240116894
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: July 12, 2023
    Publication date: April 11, 2024
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • Proteasome activity enhancing compounds
    Patent number: 11746098
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 5, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20230242557
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 3, 2023
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20230183256
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: November 18, 2022
    Publication date: June 15, 2023
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Proteasome activity enhancing compounds
    Patent number: 11560385
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 24, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20220298181
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: September 22, 2022
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • Proteasome activity enhancing compounds
    Patent number: 11242361
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: February 8, 2022
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20210188802
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 24, 2021
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20210115057
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10899751
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: January 26, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20200308198
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PROTEOSTASIS REGULATORS
    Publication number: 20200299270
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Application
    Filed: November 21, 2019
    Publication date: September 24, 2020
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • Proteostasis regulators
    Patent number: 10532996
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: January 14, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20200010461
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Application
    Filed: June 21, 2017
    Publication date: January 9, 2020
    Inventors: Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
  • Wearable Display Device
    Publication number: 20180310046
    Abstract: A content distribution system featuring a plurality of wearable display devices. Wherein the wearable display devices may display be updated in real time via data connection with content from advertisers or other organizations.
    Type: Application
    Filed: April 24, 2018
    Publication date: October 25, 2018
    Inventor: Matthew Cullen
  • Wearable Display Device
    Publication number: 20180308120
    Abstract: A content distribution system featuring a plurality of wearable display devices. Wherein the wearable display devices may display be updated in real time via data connection with content from advertisers or other organizations.
    Type: Application
    Filed: April 24, 2018
    Publication date: October 25, 2018
    Inventors: Matthew Cullen, Ruupak Nanyamka Omar
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20180282352
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 4, 2017
    Publication date: October 4, 2018
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein
  • Proteasome activity enhancing compounds
    Patent number: 9850262
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: December 26, 2017
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein
  • PROTEOSTASIS REGULATORS
    Publication number: 20170247355
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Application
    Filed: January 10, 2017
    Publication date: August 31, 2017
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen